Exhibit 4.7 Amendment to the Investor Rights Agreement dated as of March 15, 2004 (this "Amendment"), among Memory Pharmaceuticals Corp. and the investors set forth on the signature page hereto (the "Investors")...
Exhibit 4.7
Amendment to the Investor Rights Agreement dated as of
March 15, 2004 (this "Amendment"), among Memory
Pharmaceuticals Corp. and the investors set forth on
the signature page hereto (the "Investors")
------------------------------------------------------
A. The Company and the Investors entered into a Fourth Amended and
Restated Investor Rights Agreement dated as of September 11, 2003, as amended by
an Agreement dated as of December 18, 2003, among the Company, Dr. ▇▇▇▇ ▇▇▇▇▇▇
and the Investors (the "Investor Rights Agreement"). Capitalized terms used and
not otherwise defined herein shall have the meanings ascribed to such terms in
the Investor Rights Agreement.
B. The Company and the Investors wish to amend the definition of
"Initial Public Offering" in the Investor Rights Agreement.
C. Pursuant to Section 8.3 of the Investor Rights Agreement, this
Amendment requires the Company's consent and the consent in writing of holders
of at least two-thirds (2/3) of the outstanding shares of Preferred Stock.
The Company and the Investors hereby agree as follows:
1. Section 1.3 of the Investor Rights Agreement is hereby amended to
delete the definition of "Initial Public Offering" in its entirety and replace
it with the following:
"Initial Public Offering" shall mean the closing of a firm
commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended,
covering the offer and sale of Common Stock for the account of the
Company to the public at an initial public offering price per share
of not less than $7.50 (such dollar amount being subject to
equitable adjustment in the event of any stock dividend, stock
split, combination, reorganization, recapitalization or similar
event involving a change in the Common Stock) with net proceeds to
the Company of not less than $25,000,000."
2. Except as specifically amended by this Amendment, the Investor
Rights Agreement remains in full force and effect. Wherever the terms of this
Amendment and the Investor Rights Agreement conflict, this Amendment controls.
All references in the Investor Rights Agreement to "this Agreement" shall mean
the Investor Rights Agreement, as amended hereby.
3. This Agreement may be executed in counterparts, which together
shall constitute one and the same instrument.
In witness whereof, the undersigned have executed this Amendment to the
Investor Rights Agreement as of the date first above written.
Company: Memory Pharmaceuticals Corp.
By:/s/ ▇▇▇▇ ▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: Chief Executive Officer
Investors: Oxford Bioscience Partners II L.P.
By: OBP Management II L.P.
By:/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------
Name:
Title:
Oxford Bioscience Partners (Bermuda) II
Limited Partnership
By: OBP Management II (Bermuda) Limited
Partnership
By:/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------
Name:
Title:
Oxford Bioscience Partners (Adjunct) II,
L.P.
By: OBP Management II L.P.
By:/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------
Name:
Title:
Oxford Bioscience Partners (GS-Adjunct)
II, L.P.
By: OBP Management II L.P.
By:/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------
Name:
Title:
Healthcare Ventures V L.P.
By:/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Title: Administrative Partner of
HealthCare Partners V, L.P.
The General Partner of
HealthCare Ventures V, ▇.▇.
▇▇▇▇▇▇ Trust
By:
--------------------------------------
Name:
Title:
Venrock Associates
By:/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇
--------------------------------------
Name:
Title:
Venrock Associates II, L.P.
By:/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇
--------------------------------------
Name:
Title:
Alta Embarcadero Partners II LLC
By:/s/ ▇▇▇▇ ▇▇▇▇▇▇▇
--------------------------------------
Name:
Title:
GLSLP Investment I Ltd.
By:/s/ ▇▇▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Authorized Signatory:
▇▇▇▇▇▇ Representatives Limited
S.R. One Limited
By:/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
Title: General Partner
Alexandria Real Estate Equities, L.P.,
a Delaware limited partnership
By: ARE-QRS Corp.,
a Maryland general partner
By:/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Chief Financial Officer
Pharma/w Health
By:/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇ Schffery
Title: General Partner,
Orbimed Advisors, LLC
Finsbury Worldwide Pharmaceutical Trust
By:/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: General Partner,
Orbimed Advisors, LLC
▇▇▇▇▇ ▇▇▇▇▇ Worldwide Health Sciences
Portfolio
By:/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: General Partner,
Orbimed Advisors, LLC
Artal Services N.V.
By:/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: Managing Director
Venrock Entrepreneuers Fund, L.P.
By:/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
--------------------------------------
Name:
Title:
Medica II Investment (Israel), LP
By:
--------------------------------------
Name:
Title:
Medica II Investment (International), LP
By:
--------------------------------------
Name:
Title:
GIMV
/s/ ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇ By:/s/ Dirk Boogmons
----------------------- --------------------------------------
▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇ Name: Dirk Boogmons
VP Life Sciences Title: CEO
Memories Plus, LLC
By:
--------------------------------------
Name:
Title:
M&G Equities
By:/s/ ▇▇▇▇▇▇▇ Kartunkel
--------------------------------------
Name: ▇▇▇▇▇▇▇ Kartunkel
Title: Partner
-----------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
/s/ ▇▇▇▇▇ ▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇
Hare & Co., FAO Finsbury Worldwide
Pharmaceutical Trust PLC
By:
--------------------------------------
Name:
Title:
Adviesbeheer GIMV Life Sciences
/s/ ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇ By:/s/ Dirk Boogmons
----------------------- --------------------------------------
▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇ Name: Dirk Boogmons
Director Title: Director
Bioveda Fund Pte Ltd
By:
--------------------------------------
Name:
Title:
By:Bioveda Capital Pte Ltd, Its
Investment Manager
By:
--------------------------------------
Name:
Title:
Medica II Investments (P.F.)(Israel) L.P.
By:
--------------------------------------
Name:
Title:
Oxford Bioscience Partners II (Annex)
L.P.
By: OBP Management II L.P.
By:/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
--------------------------------------
Name:
Title:
The Yasuda Enterprise Development I
Limited Partnership
By: Yasuda Enterprise Development Co.,
Ltd.
By:/s/ ▇▇▇▇▇▇ ▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇
Title: President and Representative
Director
▇▇▇▇ Ghost, LLC
By:/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
--------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇, ▇▇.
Title: Manager
Mitsubishi Corporation
By:/s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
Title: General Manager
Life Sciences Business Unit
Mitsubishi International Corporation
By:/s/ Motoatsu Sakurai
--------------------------------------
Name: Motoatsu Sakwai
Title: President and CEO
CZ Specialty Chemicals, Inc.
By:/s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
Title:
-----------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, Ph.D.
-----------------------------------------
▇▇▇▇-▇▇▇▇▇▇ ▇▇▇▇, Ph.▇.
▇▇▇▇▇▇, Divincent, Allessi, Inc.
By:
--------------------------------------
Name:
Title:
Societe Generale Investment Corporation
By:/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Vice President
RHO Management Trust II
By: Rho Capital Partners, Inc.,
Investment Advisor
By:
--------------------------------------
Name:
Title:
Yamanouchi Venture Capital, LLC
By:/s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: President and Chief Financial
Officer
Alta California Partners II, L.P.
By: Alta California Management Partners
II, LLC, Its General Partner
By:/s/ ▇▇▇▇ ▇▇▇▇▇▇▇
--------------------------------------
Name:
Title:
Biomedicine L.P.
By: International Bm Biomedicine
Holdings (Cayman) Ltd., Its General
Partner
By:/s/ Illegible
--------------------------------------
Name:
Title:
/s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
--------------------------------------
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, M.D.
New England Partners Capital, L.P.
By: Nep Capital, Llc, Its General
Partner
By:
--------------------------------------
Name:
Title:
Middlegate Ventures, LLC
By:/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
--------------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇
Title: Managing Partner
-----------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ (i.t.f.)
-----------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Inc.
By:
--------------------------------------
Name:
Title: